Posttreatment Amyloid Levels and Clinical Outcomes Following Donanemab for Early Symptomatic Alzheimer Disease

Authors

Institutions

Publication Details

Journal
JAMA Neurology
Published
2025-10-13
DOI
https://doi.org/10.1001/jamaneurol.2025.3869
Citations
4
Primary Topic
Alzheimer's disease research and treatments
Type
article
Field-Weighted Citation Impact
4.66

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Posttreatment Amyloid Levels and Clinical Outcomes Following Donanemab for Early Symptomatic Alzheimer Disease

Dawn A. Brooks, Yuma Yokoi, Sergey Shcherbinin, Oskar Hansson et al.
4 citations
JAMA Neurology
Alzheimer's disease research and treatments
4.66
article

Posttreatment Amyloid Levels and Clinical Outcomes Following Donanemab for Early Symptomatic Alzheimer Disease

Dawn A. Brooks, Yuma Yokoi, Sergey Shcherbinin, Oskar Hansson, Emily C. Collins, Mark A. Mintun, Amy K. Ellinwood, Min Jung Kim, Ming Lu, John R. Sims, David S. Knopman
article en
4 citations

Abstract

No abstract available for this paper.
JAMA NeurologyVol. 82(12)
Mayo Clinic (US), Eli Lilly (United States) (US)
Eli Lilly and Company
Openalex Percentile: Top 5%
Alzheimer's disease research and treatments
4.66
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.